The Role of SPLUNC1/BPIFA1 in the host response to respiratory virus infection
Lead Research Organisation:
University of Sheffield
Department Name: Infection Immunity & Cardiovasc Disease
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The PLUNC/BPIF family of glycoproteins are constitutively expressed in the respiratory tract of mammals. They show structural similarities to BPI and LBP, proteins critical to host defence against bacterial pathogens. However, the function of BPIF proteins is unknown. In this grant we are focussing on SPLUNC1 or BPIFA1. We have shown that BPIFA1 is produced in respiratory epithelial cells, and that after infection with Murine gamma-herpesvirus 68 (MHV-68) and Influenza A virus (IAV), its production is modulated. Using bpifa1-/- mice, we have also shown that it is involved in the defence against IAV. We therefore believe that BPIAF1 is involved in the host defence to virus infection in the respiratory tract. The aims of this project are:
1). To elucidate the temporal and spatial expression of BPIFA1 and its function in vivo.
2). To determine the functions of BPIFA1 in epithelial host defence in vitro.
3). To dissect the mechanisms involved in the regulation of SPLUNC1 expression and action.
We will use bpifa1-/- mice, an in vitro air-liquid interface culture system based on these mice and transcriptional profiling to achieve these aims. We will use two complimentary experimental pathogens. IAV, an RNA virus that produces an acute, lytic infection and MHV-68, a DNA virus that is less cytopathic and forms a persistent/latent infection. Both are relevant to disease in animals and have good sets of specific reagents that will allow the study of the host response in mice. The results will significantly enhance our understanding of fundamental aspects of host responses to virus infection in the lung as well as respiratory biology. In turn this may lead to novel approaches to improving antiviral therapies or therapeutic interventions against the consequences of viral infection.
1). To elucidate the temporal and spatial expression of BPIFA1 and its function in vivo.
2). To determine the functions of BPIFA1 in epithelial host defence in vitro.
3). To dissect the mechanisms involved in the regulation of SPLUNC1 expression and action.
We will use bpifa1-/- mice, an in vitro air-liquid interface culture system based on these mice and transcriptional profiling to achieve these aims. We will use two complimentary experimental pathogens. IAV, an RNA virus that produces an acute, lytic infection and MHV-68, a DNA virus that is less cytopathic and forms a persistent/latent infection. Both are relevant to disease in animals and have good sets of specific reagents that will allow the study of the host response in mice. The results will significantly enhance our understanding of fundamental aspects of host responses to virus infection in the lung as well as respiratory biology. In turn this may lead to novel approaches to improving antiviral therapies or therapeutic interventions against the consequences of viral infection.
Planned Impact
Respiratory virus infections are of global significance to both the human and animal populations. The zoonotic potential of influenza and the implications of emerging new strains are well recognised by both the scientific community and the general public. Improved understanding of the pathogenesis of infection and the host response to these pathogens is critical in improving treatment and management of respiratory disease and the associated morbidity and mortality. This work aims to further this understanding by looking at the role of SPLUNC1/BPIFA1 in the innate responses of the host respiratory tract following infection with influenza virus and gamma-herpesviruses.
The academic impact of this work therefore will be to further the knowledge of the host response to viral infection, providing the foundations of academic knowledge and understanding on which future advancements in treatment and disease control can be built. The use of the multi-disciplinary approach as proposed here brings together expertise in respiratory cell and molecular biology, molecular virology and veterinary pathology, thereby maximising the potential outputs of the research. This is also advantageous to the RAs in providing the experience and training involving multiple fields fostering a multi-disciplinary approach and its advantages for enhanced, productive science as well as allowing them to develop a range of transferable skills that will enhance their career development. This is achieved by collaboration between the Universities of Sheffield and Liverpool and is furthered by collaboration and knowledge exchange with staff of Investigative and Translational Pathology at AstraZeneca. This cooperation will enable optimal use of imaging techniques and image analysis, allowing staff and students at the Universities to benefit from AstraZeneca's expertise, strengthening existing links between the University of Liverpool and AstraZeneca and establishing a mutually beneficial relationship for future collaboration.
Cooperation between academic and industrial institutions also contributes to the economic impact of research by enhancing the research capabilities, knowledge exchange and skills of workers in both sectors. Exposure to both academic and industry in the course of this work will be of benefit to postgraduate students who will gain experience of both workplaces and the opportunities of career development in both sectors.
The societal impact of furthering the understanding of the host response to infection with Influenza virus on the health of the individual and the wider population is significant. Likewise, gamma-herpesviruses, cause significant morbidity and mortality in humans and animals. Contribution to the improved treatment of individual high risk patients where infection with Influenza virus has a higher morbidity and mortality than the general population, or increased understanding of the risk factors associated with epidemic strains, both are important in the future of prevention and control of Influenza infection, in both veterinary species and the human population.
The academic impact of this work therefore will be to further the knowledge of the host response to viral infection, providing the foundations of academic knowledge and understanding on which future advancements in treatment and disease control can be built. The use of the multi-disciplinary approach as proposed here brings together expertise in respiratory cell and molecular biology, molecular virology and veterinary pathology, thereby maximising the potential outputs of the research. This is also advantageous to the RAs in providing the experience and training involving multiple fields fostering a multi-disciplinary approach and its advantages for enhanced, productive science as well as allowing them to develop a range of transferable skills that will enhance their career development. This is achieved by collaboration between the Universities of Sheffield and Liverpool and is furthered by collaboration and knowledge exchange with staff of Investigative and Translational Pathology at AstraZeneca. This cooperation will enable optimal use of imaging techniques and image analysis, allowing staff and students at the Universities to benefit from AstraZeneca's expertise, strengthening existing links between the University of Liverpool and AstraZeneca and establishing a mutually beneficial relationship for future collaboration.
Cooperation between academic and industrial institutions also contributes to the economic impact of research by enhancing the research capabilities, knowledge exchange and skills of workers in both sectors. Exposure to both academic and industry in the course of this work will be of benefit to postgraduate students who will gain experience of both workplaces and the opportunities of career development in both sectors.
The societal impact of furthering the understanding of the host response to infection with Influenza virus on the health of the individual and the wider population is significant. Likewise, gamma-herpesviruses, cause significant morbidity and mortality in humans and animals. Contribution to the improved treatment of individual high risk patients where infection with Influenza virus has a higher morbidity and mortality than the general population, or increased understanding of the risk factors associated with epidemic strains, both are important in the future of prevention and control of Influenza infection, in both veterinary species and the human population.
Publications
Akram KM
(2018)
An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus infection.
in Mucosal immunology
Leeming GH
(2015)
Gammaherpesvirus infection modulates the temporal and spatial expression of SCGB1A1 (CCSP) and BPIFA1 (SPLUNC1) in the respiratory tract.
in Laboratory investigation; a journal of technical methods and pathology
Mulay A
(2021)
The transcriptional landscape of the cultured murine middle ear epithelium in vitro.
in Biology open
Mulay A
(2016)
An in vitro model of murine middle ear epithelium.
in Disease models & mechanisms
Mulay A
(2018)
Loss of the homeostatic protein BPIFA1, leads to exacerbation of otitis media severity in the Junbo mouse model.
in Scientific reports
Description | We were able to identify a key role for BPIFA1 in initial response to influenza A infection in the airways. The award had been completed but the work is still ongoing. Some data generated through the award has been included in a publication for 2016 and our first significant paper has been published in Mucosal Immunology. We also were able to leverage the funding to generate some additional results that have appeared in two additional papers. The transcriptional data we have generated will form the basis of additional publications. |
Exploitation Route | Other may make use of our culture models (both tracheal and ear cells cultures). We also trained researchers from two other labs in the culture techniques. Both have used thsi training to publish their own papers. We have also generated some transcriptomic and proteomic data sets that will be available to others when they are published. |
Sectors | Healthcare,Pharmaceuticals and Medical Biotechnology |
Description | BPIFA1: from anti-viral peptide to immunomodulator |
Amount | £93,304 (GBP) |
Funding ID | BB/R019479/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2018 |
End | 06/2021 |
Description | Liverpool |
Organisation | University of Liverpool |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The partnership with Professor James Stewart's group is a direct collaboration as our grants are linked. |
Collaborator Contribution | The partnership with Professor James Stewart's group is a direct collaboration as our grants are linked. |
Impact | We are currently co-writing papers |
Start Year | 2009 |